BRAF Mutation Predicts a Poorer Clinical Prognosis for Papillary Thyroid Cancer
Xing M, Westra WH, Tufano RP, Cohen Y, Rosenbaum E, Rhoden KJ, Carson KA, Vasko V, Larin A, Tallini G, Tolaney S, Holt EH, Hui P, Umbricht CB, Basaria S, Ewertz M, Tufaro AP, Califano JA, Ringel MD, Zeiger MA, Sidransky D, Ladenson PW. BRAF Mutation Predicts a Poorer Clinical Prognosis for Papillary Thyroid Cancer. The Journal Of Clinical Endocrinology & Metabolism 2005, 90: 6373-6379. PMID: 16174717, DOI: 10.1210/jc.2005-0987.Peer-Reviewed Original ResearchConceptsPapillary thyroid cancerBRAF mutation statusBRAF mutationsClinicopathological predictorsRisk stratificationClinicopathological outcomesThyroid cancerPTC subtypesMutation statusTumor stage III/IVStage I/II diseaseMultivariate analysisTumor BRAF mutation statusStage III/IVInitial tumor characteristicsLymph node metastasisPoor clinicopathological outcomesInitial surgeryRecurrent diseaseClinical courseIndependent predictorsNode metastasisClinicopathological characteristicsSubsequent recurrenceTreatment failure